Multiple myeloma trials in Japan

In Japan 34 Also abroad 703

34 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Bunkyo-ku, Kagoshima, Kobe, Kofu, Koto, Kyoto, Maebashi, Matsuyama, Okayama, Shibukawa, Shiwa-gun Yahaba-cho, Toyohashi, Yamagata
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Kyoto, Shibuya-ku
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1Taking people
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Bunkyo-ku, Kashiwa-shi, Koto-ku, Kumamoto, Mibu
Age
18 years and over
People
135 worldwide
Run by
AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Miyagi, Nara, Numakunai, Osaka, Sapporo, Shibuya-Ku, Suita, Tokyo, Yamagata
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 1/2Not yet taking people in Japan
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Where
Bunkyo-ku, Shibuya-ku, tabashi City
Age
18 years to 70 years
People
17
Run by
Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07510100
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Bunkyō City, Bunkyo-ku, Fukuoka, Fukushima, Hokkaido, Isehara-Shi, Kashiwa-shi, Miyagi, Nagasaki, Okayama, Osaka, Yoshida-gun
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
No phaseTaking people
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Where
Kumamoto, Toyokawa
People
50 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06357754